NFKB1 and neuroblastoma: Furthermore, in NB cells, including the chemoresistant LA-N-6 cell line, ixazomib synergizes with dox treatment by enhancing the cytotoxicity of dox and overcoming dox resistance by stabilizing the IκBα protein and inhibiting dox-induced NF-κB activation.